Literature DB >> 414058

Significance of red-cell irregular antibodies in the obstetric patient.

R J Pepperell, J U Barrie, J R Fliegner.   

Abstract

Irregular antibodies were identified in 1.3% of obstetric patients who were delivered at the Royal women's Hospital, Melbourne. The most common antibodies found were anti-P1 and anti-Lewis, but, although these antibodies may cause difficulty in obtaining compatible blood if transfusion is required, they were not associated with haemolytic disease of the newborn. Immunization with other irregular antibodies, especially Rhesus subtype and Kell, may occur due to pregnancy alone or follow the combination of pregnancy and incompatible blood transfusion. Irrespective of the initial cause of immunization, these antibodies are often associated with haemolytic disease of the newborn which may be severe enough to result in perinatal death. As most irregular antibodies are found in patients with Rh-positive blood, the need for screening of all antenatal patients in each pregnancy must be recognized.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 414058     DOI: 10.5694/j.1326-5377.1977.tb117729.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  3 in total

1.  Relationship between previous maternal transfusions and haemolytic disease of the foetus and newborn mediated by non-RhD antibodies.

Authors:  Slavica Dajak; Srđana Culić; Vedran Stefanović; Jelena Lukačević
Journal:  Blood Transfus       Date:  2013-03-05       Impact factor: 3.443

2.  Haemolytic disease of the newborn infant. Long term efficiency of the screening and the prevention of alloimmunization in the mother: thirty years of experience.

Authors:  P Moncharmont; F Juron Dupraz; M Vignal; D Rigal; F Meyer; P Debeaux
Journal:  Arch Gynecol Obstet       Date:  1991       Impact factor: 2.344

3.  Red blood cell antibody screening in pregnancy.

Authors:  Shanthala A M Devi; Vanamala A Alwar; S Sitalakshmi; Karuna Rameshkumar; Rita Mhaskar
Journal:  Asian J Transfus Sci       Date:  2011-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.